[go: up one dir, main page]

US20050186251A1 - Method of promoting osteogenesis - Google Patents

Method of promoting osteogenesis Download PDF

Info

Publication number
US20050186251A1
US20050186251A1 US11/104,771 US10477105A US2005186251A1 US 20050186251 A1 US20050186251 A1 US 20050186251A1 US 10477105 A US10477105 A US 10477105A US 2005186251 A1 US2005186251 A1 US 2005186251A1
Authority
US
United States
Prior art keywords
poly
polymer
nmp
lactide
implant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/104,771
Inventor
Eija Pirhonen
Jan Nieuwenhuis
Auvo Kaikkonen
Tuomo Nieminen
Franz Weber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Inion Ltd
Original Assignee
Inion Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inion Ltd filed Critical Inion Ltd
Priority to US11/104,771 priority Critical patent/US20050186251A1/en
Publication of US20050186251A1 publication Critical patent/US20050186251A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/58—Materials at least partially resorbable by the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/18—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease

Definitions

  • the present invention relates to novel polymer compositions that are useful in the manufacture of medical implants. More particularly, embodiments of the invention relate to polymer compositions having osteogenic properties.
  • the polymer compositions are biodegradable or bioresorbable and they can be fashioned into medical implants for implantation in the body. Implants having osteogenic properties and methods of making said implants are also disclosed.
  • the healing process of bone is a complicated cascade of events. Rapid and diverse events are activated by a fracture or osteotomy of a bone in order to limit the loss of blood and initiate cellular migration resulting in repair. Current concepts suggest that these cellular events are controlled to a large part by growth factors, low-molecular-weight glycoproteins, inducing migration, proliferation and differentiation of an appropriate subset of cells in the site of the fracture.
  • Osteoinduction is a process where any substance, stimulation etc. starts or enhances a cellular response resulting in a bone formation process.
  • Growth factors are a wide group of molecules known to possess this effect.
  • bone morphogenetic proteins BMP are the only growth factors known to induce bone formation heterotopically by inducing undifferentiated mesenchymal cells to differentiate into osteoblasts. Consequently, several BMPs are shown to boost the bone healing process when supplementary doses are given.
  • U.S. Pat. No. 5,725,491 discloses a biodegradable film dressing as a delivery system of various therapeutic agents, such as BMPs.
  • the therapeutic agent is delivered from the film dressing in a certain and controlled release rate.
  • BMPs are produced by genetic engineering, which is still rather expensive. Also, delivery of a correct dose of BMPs is difficult and presents great challenges for the future.
  • An object of the present invention is to provide novel resorbable polymer compositions having osteogenic properties so as to alleviate the above disadvantages. Another object is to provide novel resorbable implants having osteogenic properties. A further object is to provide methods of making resorbable implants having osteogenic properties.
  • resorbable polymer compositions comprising a base material including a polymer matrix of resorbable polymer(s) or copolymer(s) and N-methyl-2-pyrrolidone (NMP).
  • NMP N-methyl-2-pyrrolidone
  • the polymer matrix comprises Polylactide/Polyglycolide/Trimethylene carbonate copolymer (PLA/PGA/TMC) with a composition of 80/10/10.
  • PLA/PGA/TMC Polylactide/Polyglycolide/Trimethylene carbonate copolymer
  • the polymer matrix comprises Poly D, L-lactide/Poly L-lactide/Trimethylene carbonate copolymer (PLDLA/PLA/TMC) with a composition of 55/40/5.
  • PLDLA/PLA/TMC Poly L-lactide/Poly L-lactide/Trimethylene carbonate copolymer
  • the polymer matrix comprises 80 wt-% P(L/DL)LA (70/30) and 20 wt-% PLLA/TMC (70/30).
  • the implant is a membrane.
  • the method comprises the steps of selecting polymer(s) or copolymer(s) of a polymer matrix of the implant, mixing said polymer(s) or copolymer(s) to form the polymer matrix, forming the implant from said polymer matrix, and adding NMP to the implant in an amount imparting osteogenic properties for said implant.
  • the method comprises the steps of selecting polymer(s) or copolymer(s) of a polymer matrix of the implant, adding NMP to the polymer matrix in an amount imparting osteogenic properties for the implant, and forming the implant from the mixture of said polymer matrix and NMP.
  • An advantage of polymer compositions, implants and methods of the invention is that substantially inexpensive products are achieved as compared with known solutions enhancing bone healing.
  • FIG. 1 a is a microscope view of a histological section of a defect created in rabbit calvarial bone where said defect is covered by a (PLA/PGA/TMC) 80/10/10 membrane treated with NMP as described in example 1,
  • FIG. 1 b is a second microscope view of a histological section of a defect created in rabbit calvarial bone where said defect is covered by an OsseoQuest membrane,
  • FIG. 1 c is a third microscope view of a histological section of a defect created in rabbit calvarial bone where said defect is without any membrane, and
  • FIG. 2 is a graph showing repair of rabbit calvarial bone defects.
  • the present invention relates to a combination of N-methyl-2-pyrrolidone (NMP) and resorbable polymers or copolymers.
  • NMP N-methyl-2-pyrrolidone
  • the invention is based on the unexpected realization that by combining a resorbable matrix material and NMP in a certain ratio, an implant having osteogenic properties is achieved.
  • the implant thus induces bone growth due to the osteogenic properties of the polymer composition and enhances bone healing after osteotomies and bone fractures.
  • the implant forms include, but are not limited to, membranes, films, plates, mesh plates, screws, taps or other formed pieces.
  • the implant can be prepared for example of polyglycolide, polylactides, polycaprolactones, polytrimethylenecarbonates, polyhydroxybutyrates, polyhydroxyvalerates, polydioxanones, polyorthoesters, polycarbonates, polytyrosinecarbonates, polyorthocarbonates, polyalkylene oxalates, polyalkylene succinates, poly(malic acid), poly(maleic anhydride), polypeptides, polydepsipeptides, polyvinylalcohol, polyesteramides, polyamides, polyanhydrides, polyurethanes, polyphosphazenes, polycyanoacrylates, polyfumarates, poly(amino acids), modified polysaccharides (like cellulose, starch, dextran, chitin, chitosan, etc.), modified proteins (like collagen, casein, fibrin, etc.) and their copolymers, terpolymers or combinations or mixtures or polymer blends thereof.
  • Polyglycolide poly(L-lactide-co-glycolide), poly(D,L-lactide-co-glycolide), poly(L-lactide), poly(D,L-lactide), poly(L-lactide-co-D,L-lactide), polycaprolactone, poly(L-lactide-co-caprolactone), poly(D,L-lactide-co-caprolactone) polytrimethylenecarbonate, poly(L-lactide-co-trimethylenecarbonate), poly(D,L-lactide-co-trimethylenecarbonate), polydioxanone and copolymers, terpolymers and polymer blends thereof are highly preferred polymers.
  • Polylactide/Polyglycolide/Trimethylene carbonate copolymer (PLA/PGA/TMC), with a composition of 80/10/10, granulates were compression moulded to form a film with a thickness of 0.2 mm. Used compression temperature was 180° C. and pressure 130 bar. From the film 10 rectangular pieces were cut, each with a width of 20 mm.
  • the weight of the individual film pieces were measured with balance with an accuracy of 1 mg.
  • the film pieces were then immersed individually into NMP for 30 seconds. After immersion the film pieces were air dried for 20 minutes and the weight of the pieces was measured again.
  • the weight of the film pieces before and after immersion into NMP are shown in table 1.
  • the average amount of NMP diffused into polymeric film was 44.19%.
  • TABLE 1 The weight of the film pieces before and after immersion into NMP Weight before Weight after NMP Polymer NMP immersion into immersion into content content content NMP (mg) NMP (mg) (mg) (%) (%) 56.41 98.95 42.54 57.01 42.99 67.29 115.40 48.11 58.31 41.69 60.22 105.40 45.18 57.13 42.87 59.77 101.35 41.58 58.97 41.03 56.48 110.25 53.77 51.23 48.77 66.62 118.52 51.9 56.21 43.79 64.16 114.42 50.26 56.07 43.93 62.58 114.24 51.66 54.78 45.22 56.29 104.32 48.03 53.96 46.04 62.53 114.82 52.29 54.46
  • GTR membranes produced with the method described here in were used in a comparable rabbit study disclosed in example 2.
  • the study design included eight rabbits with four 6-mm artificial craniotomy defects each.
  • the defects were treated with biodegradable membranes and a commercial biodegradable OsseoQuest membrane as shown in table 2.
  • Controls treated without any membranes were included, too.
  • the matrixes of the resorbable membranes are also presented in table 2.
  • the rabbits were sacrificed 4 weeks after the operation and the calvarial bone excised. Thorough histological analysis was performed in order to assess the degree and type of bone regeneration.
  • FIGS. 1 a to 1 c illustrate examples of some histological sections from the middle of the defect. It is clearly evident that the bone formed during the 4-week repair phase is more a cancellous bone than a cortical bone. A cellular interaction with the membrane was not observed.
  • FIG. 2 shows the percentage of a full-thickness repair of rabbit calvarial bone defects.
  • the middle sections of the defects, 6 mm in diameter in the calvarial bone were evaluated.
  • the percentage of repair was determined by pixel number of the defect filled with bone ⁇ 100/pixel number of the defect area.
  • the different membranes are specified by name. ‘Control’ means the defect without the application of a membrane.
  • the membranes of the present invention i.e. E1M-3 NMP and E1M-11 NMP
  • E1M-3 NMP and E1M-11 NMP increase markedly the healing response in the defect as compared with the membranes with an identical polymeric composition, i.e. E1M-3, E1M-11, that do not comprise NMP.
  • NMP is added to the polymer matrix that has been already fashioned into the form of a medical implant.
  • Polymer compositions were prepared by dry-mixing commercially available granular-form base materials with commercially available copolymer additives.
  • the material composition was 80 wt-% P(L/DL)LA (70/30) and 20 wt-% PLLA/TMC (70/30).
  • the components were weighed according to a desired weight ratio into a container which was then rotated in a Turbula T2F shaker mixer for 30 minutes until a homogenous dry mixture was obtained.
  • the resulting mixture was then dried in vacuum at 60° C. for 8 to 12 hours and thereafter melt-blended and injection-moulded in to plate-shaped test pieces.
  • the injection-moulding machine used was a fully electric Fanuc Roboshot Alpha i30A injection-moulding machine with a mould clamping force of 300 kN.
  • the injection unit was equipped with high speed (max. 66 cm 3 /s to 330 mm/s), high pressure (max. 2500 bar) injection options.
  • the barrel diameter was 16 mm and it was equipped with three-band heater zones, a standard profile anticorrosion screw and a standard open nozzle with a 2.5 mm hole.
  • the extruder melt-blending and homogenization conditions of the material during the metering phase of the process included a back pressure of 40 to 60 bar, a screw speed of 60 to 100 rpm and barrel temperatures of 160 to 230° C.
  • Injection moulding conditions included a nozzle temperature of 180 to 230° C., an injection speed of 80 to 300 mm/s, a maximum injection pressure of 2500 bar, a pack pressure of 1000 to 2300 bar for 3 to 8 s, a cooling time of 10 to 22 s and a mould temperature of 20 to 30° C.
  • the total cycle time was 20 to 40 s consisting of the following phases during one injection-moulding process cycle: closing of the mould, injection of the molten polymer into the mould, pack pressure, cooling while extruder was metering for the next cycle during cooling phase, opening the mould and ejection of article from the mould.
  • the plates were sterilized by gamma irradiation with a nominal dose of 25 kGy. After sterilisation, the plates were submerged in NMP (1-Methyl-2-pyrrolidinone, 99%, Acros Organics, Inc., USA) for 30 seconds. After submerging the plates were set for 30 minutes on a plastic holder at room conditions at 20° C. Thickness, length and mass of the plates were measured before submerging and 30 minutes thereafter. Dimensions were measured with a slide gauge and mass with an analysis balance. Additionally, 30, 60 and 120 minutes after the submerging of the plate, it was bent to 45° angle to find out softening and bending characteristics of the plate.
  • NMP 1-Methyl-2-pyrrolidinone
  • the thickness of the plate was increased 13% and its mass was increased 22% due to the submerging of the plate in NMP.
  • the increase of the mass can be seen as the diffusion of NMP into the plate.
  • the increase of the thickness is due to the swelling of the outer layer of the plate.
  • the thickness of the swollen outer layer of the plate was ca. 0.15 mm.
  • the length was not changed due to the submerging. Moreover, 30 minutes after submerging the plate was softened and bendable by hand.
  • Resorbable polymer matrix absorbs NMP when immersed into it. Thereafter, an implant loaded with NMP is implanted into the body, and NMP is released gradually during a certain period of time. If the rate of releasing is appropriate, NMP owns osteogenic properties. As with almost any pharmaceuticals, the concentration of NMP must be within certain limits, called a therapeutic window. Below the window, NMP is inefficacious. Correspondingly, above the window, NMP presents an adverse event by inhibiting certain proteins, other molecules or cell lines.
  • the NMP content is preferably between 0.05 and 50 weight- %, more preferably between 0.1 and 10 weight-%.
  • NMP is mixed with a polymer matrix or one of its components before the polymer matrix is fashioned into the form of a medical implant.
  • the mixing can take place in an extruder, in a mixer or similar equipment known per se.
  • NMP may be applied to the implant as well by packing said implant into a container with NMP already in the production process. NMP will be absorbed to the polymer matrix of the implant during storage in said container.
  • the polymer composition of the present invention can be fashioned into implants by injection moulding, compression moulding, extrusion or with another melt-moulding process known by persons skilled in the art.
  • Example 4 presents one preferred embodiment of the present invention, where the implant is a barrier membrane in Guided Tissue Regeneration (GTR) to treat a periodontal defect.
  • GTR Guided Tissue Regeneration
  • the membrane comprises PLA/PGA-matrix polymers.
  • the membrane is packaged in a slot of a package, such as a plastic blister.
  • the preparation of the membrane is conducted as one stage of surgical operation as follows:
  • NMP is allowed to diffuse into the polymer matrix of the membrane for 15 to 20 minutes.
  • the membrane is ready for use as a barrier between the gingival soft tissue and the healing bone tissue and/or periodontal tissues in order to prevent the gingival soft tissue filling the defect side. In the conditions of a normal operating theater temperature and humidity, the membrane stays malleable for several hours.
  • Implants of the invention can be used for example in guided bone regeneration applications, where the effect of a NMP loaded barrier membrane is required to avoid soft tissue ingrowth in the area where new bone formation is required, and to enhance bone regeneration.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Transplantation (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Materials For Medical Uses (AREA)
  • Medicinal Preparation (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Prostheses (AREA)

Abstract

Novel polymer compositions that are useful in the manufacture of medical implants, implants having osteogenic properties and methods of making said implants are disclosed. Polymer compositions comprise a base material including a polymer matrix of resorbable polymer(s) or copolymer(s), and N-methyl-2-pyrrolidone (NMP), wherein NMP is present in an amount imparting osteogenic properties for the composition.

Description

    FIELD OF THE INVENTION
  • The present invention relates to novel polymer compositions that are useful in the manufacture of medical implants. More particularly, embodiments of the invention relate to polymer compositions having osteogenic properties. The polymer compositions are biodegradable or bioresorbable and they can be fashioned into medical implants for implantation in the body. Implants having osteogenic properties and methods of making said implants are also disclosed.
    • BACKGROUND OF THE INVENTION
  • The healing process of bone is a complicated cascade of events. Rapid and diverse events are activated by a fracture or osteotomy of a bone in order to limit the loss of blood and initiate cellular migration resulting in repair. Current concepts suggest that these cellular events are controlled to a large part by growth factors, low-molecular-weight glycoproteins, inducing migration, proliferation and differentiation of an appropriate subset of cells in the site of the fracture.
  • Despite of the amount of known details the bone healing as a whole is still a poorly understood process. Based on this lacking information and experimental data research has revealed several methods to enhance bone growth, such as mechanical stimulation, electromagnetic fields, low-intensity ultrasound, osteoconductive materials, for instance hydroxyapatite, tricalcium phosphate, bioactive glass etc., and osteoinductive materials, such as growth factors.
  • Osteoinduction is a process where any substance, stimulation etc. starts or enhances a cellular response resulting in a bone formation process. Growth factors are a wide group of molecules known to possess this effect. According to the current knowledge, bone morphogenetic proteins (BMP) are the only growth factors known to induce bone formation heterotopically by inducing undifferentiated mesenchymal cells to differentiate into osteoblasts. Consequently, several BMPs are shown to boost the bone healing process when supplementary doses are given.
  • For example, U.S. Pat. No. 5,725,491 discloses a biodegradable film dressing as a delivery system of various therapeutic agents, such as BMPs. The therapeutic agent is delivered from the film dressing in a certain and controlled release rate. However, BMPs are produced by genetic engineering, which is still rather expensive. Also, delivery of a correct dose of BMPs is difficult and presents great challenges for the future.
  • Known materials, methods and implants are expensive and exploitation of such materials, methods and implants is constrained.
    • BRIEF DESCRIPTION OF THE INVENTION
  • An object of the present invention is to provide novel resorbable polymer compositions having osteogenic properties so as to alleviate the above disadvantages. Another object is to provide novel resorbable implants having osteogenic properties. A further object is to provide methods of making resorbable implants having osteogenic properties.
  • These objects are achieved by providing resorbable polymer compositions, resorbable implants and methods of making resorbable implants comprising a base material including a polymer matrix of resorbable polymer(s) or copolymer(s) and N-methyl-2-pyrrolidone (NMP).
  • According to one embodiment of the invention, the polymer matrix comprises Polylactide/Polyglycolide/Trimethylene carbonate copolymer (PLA/PGA/TMC) with a composition of 80/10/10.
  • According to another embodiment of the invention, the polymer matrix comprises Poly D, L-lactide/Poly L-lactide/Trimethylene carbonate copolymer (PLDLA/PLA/TMC) with a composition of 55/40/5.
  • According to a third embodiment of the invention, the polymer matrix comprises 80 wt-% P(L/DL)LA (70/30) and 20 wt-% PLLA/TMC (70/30).
  • According to a fourth embodiment of the invention, the implant is a membrane.
  • According to one embodiment of the method of the invention, the method comprises the steps of selecting polymer(s) or copolymer(s) of a polymer matrix of the implant, mixing said polymer(s) or copolymer(s) to form the polymer matrix, forming the implant from said polymer matrix, and adding NMP to the implant in an amount imparting osteogenic properties for said implant.
  • According to another embodiment of the method of the invention, the method comprises the steps of selecting polymer(s) or copolymer(s) of a polymer matrix of the implant, adding NMP to the polymer matrix in an amount imparting osteogenic properties for the implant, and forming the implant from the mixture of said polymer matrix and NMP.
  • An advantage of polymer compositions, implants and methods of the invention is that substantially inexpensive products are achieved as compared with known solutions enhancing bone healing.
    • BRIEF DESCRIPTION OF THE DRAWINGS
  • In the following the invention will be described in greater detail by means of preferred embodiments with reference to the attached drawings, in which
  • FIG. 1 a is a microscope view of a histological section of a defect created in rabbit calvarial bone where said defect is covered by a (PLA/PGA/TMC) 80/10/10 membrane treated with NMP as described in example 1,
  • FIG. 1 b is a second microscope view of a histological section of a defect created in rabbit calvarial bone where said defect is covered by an OsseoQuest membrane,
  • FIG. 1 c is a third microscope view of a histological section of a defect created in rabbit calvarial bone where said defect is without any membrane, and
  • FIG. 2 is a graph showing repair of rabbit calvarial bone defects.
    • DETAILED DESCRIPTION OF THE INVENTION
  • The present invention relates to a combination of N-methyl-2-pyrrolidone (NMP) and resorbable polymers or copolymers. The invention is based on the unexpected realization that by combining a resorbable matrix material and NMP in a certain ratio, an implant having osteogenic properties is achieved. The implant thus induces bone growth due to the osteogenic properties of the polymer composition and enhances bone healing after osteotomies and bone fractures.
  • The implant forms include, but are not limited to, membranes, films, plates, mesh plates, screws, taps or other formed pieces.
  • The implant can be prepared for example of polyglycolide, polylactides, polycaprolactones, polytrimethylenecarbonates, polyhydroxybutyrates, polyhydroxyvalerates, polydioxanones, polyorthoesters, polycarbonates, polytyrosinecarbonates, polyorthocarbonates, polyalkylene oxalates, polyalkylene succinates, poly(malic acid), poly(maleic anhydride), polypeptides, polydepsipeptides, polyvinylalcohol, polyesteramides, polyamides, polyanhydrides, polyurethanes, polyphosphazenes, polycyanoacrylates, polyfumarates, poly(amino acids), modified polysaccharides (like cellulose, starch, dextran, chitin, chitosan, etc.), modified proteins (like collagen, casein, fibrin, etc.) and their copolymers, terpolymers or combinations or mixtures or polymer blends thereof. Polyglycolide, poly(L-lactide-co-glycolide), poly(D,L-lactide-co-glycolide), poly(L-lactide), poly(D,L-lactide), poly(L-lactide-co-D,L-lactide), polycaprolactone, poly(L-lactide-co-caprolactone), poly(D,L-lactide-co-caprolactone) polytrimethylenecarbonate, poly(L-lactide-co-trimethylenecarbonate), poly(D,L-lactide-co-trimethylenecarbonate), polydioxanone and copolymers, terpolymers and polymer blends thereof are highly preferred polymers.
    • EXAMPLE 1
  • Polylactide/Polyglycolide/Trimethylene carbonate copolymer (PLA/PGA/TMC), with a composition of 80/10/10, granulates were compression moulded to form a film with a thickness of 0.2 mm. Used compression temperature was 180° C. and pressure 130 bar. From the film 10 rectangular pieces were cut, each with a width of 20 mm.
  • The weight of the individual film pieces were measured with balance with an accuracy of 1 mg. The film pieces were then immersed individually into NMP for 30 seconds. After immersion the film pieces were air dried for 20 minutes and the weight of the pieces was measured again.
  • The weight of the film pieces before and after immersion into NMP are shown in table 1. The average amount of NMP diffused into polymeric film was 44.19%.
    TABLE 1
    The weight of the film pieces before
    and after immersion into NMP
    Weight before Weight after NMP Polymer NMP
    immersion into immersion into content content content
    NMP (mg) NMP (mg) (mg) (%) (%)
    56.41 98.95 42.54 57.01 42.99
    67.29 115.40 48.11 58.31 41.69
    60.22 105.40 45.18 57.13 42.87
    59.77 101.35 41.58 58.97 41.03
    56.48 110.25 53.77 51.23 48.77
    66.62 118.52 51.9 56.21 43.79
    64.16 114.42 50.26 56.07 43.93
    62.58 114.24 51.66 54.78 45.22
    56.29 104.32 48.03 53.96 46.04
    62.53 114.82 52.29 54.46 45.54
  • GTR membranes produced with the method described here in were used in a comparable rabbit study disclosed in example 2.
    • EXAMPLE 2
  • This rabbit study shows the osteogenetic effect of PLA/PGA/TMC and PLDLA/PLA/TMC membranes when treated with NMP. The details of the tested membranes can be found in the following table 2.
    TABLE 2
    Materials and codes of example 2
    Code Materials
    E1M-11 NMP PLA/PGA/TMC (80/10/10), treated
    with NMP (see EXAMPLE 1)
    E1M-11 PLA/PGA/TMC (80/10/10)
    E1M-3 NMP PLDLA/PLA/TMC (55/40/5), treated
    with NMP (as in EXAMPLE 1)
    E1M-3 PLDLA/PLA/TMC (55/40/5)
    OsseoQuest PLA/PGA/TMC supplier W. L.
    GORE & Associates, Inc.
    E1M-11 with holes PLA/PGA/TMC (80/10/10), with holes
    manufactured using Laser
    TMC/PLA PLA/TMC (70/30)
  • The study design included eight rabbits with four 6-mm artificial craniotomy defects each. The defects were treated with biodegradable membranes and a commercial biodegradable OsseoQuest membrane as shown in table 2. Controls treated without any membranes were included, too. The matrixes of the resorbable membranes are also presented in table 2.
  • The rabbits were sacrificed 4 weeks after the operation and the calvarial bone excised. Thorough histological analysis was performed in order to assess the degree and type of bone regeneration.
  • FIGS. 1 a to 1 c illustrate examples of some histological sections from the middle of the defect. It is clearly evident that the bone formed during the 4-week repair phase is more a cancellous bone than a cortical bone. A cellular interaction with the membrane was not observed.
  • FIG. 2 shows the percentage of a full-thickness repair of rabbit calvarial bone defects. The middle sections of the defects, 6 mm in diameter in the calvarial bone were evaluated. The percentage of repair was determined by pixel number of the defect filled with bone×100/pixel number of the defect area. The different membranes are specified by name. ‘Control’ means the defect without the application of a membrane.
  • Evaluation of the level of a full-thickness repair of the bone defect revealed that the use of membranes improved bone healing. The percentage of repair without a membrane, i.e. ‘control’, was 31.3±4.1% of the defect area of the middle section. Essential improvement of bone healing as compared with the control was achieved with OsseoQuest (55.78±9.9%), and E1M-11 NMP (77.6±8.8%). A direct comparison of bone healing enhanced by OsseoQuest and E1M-11 NMP shows a clearly better healing with E1M-11 NMP. Furthermore, E1M-3NMP shows a healing effect essentially similar to OsseoQuest.
  • As shown in FIG. 2 the membranes of the present invention, i.e. E1M-3 NMP and E1M-11 NMP, increase markedly the healing response in the defect as compared with the membranes with an identical polymeric composition, i.e. E1M-3, E1M-11, that do not comprise NMP.
    • EXAMPLE 3
  • According to one embodiment of the method of the present invention, NMP is added to the polymer matrix that has been already fashioned into the form of a medical implant.
  • Polymer compositions were prepared by dry-mixing commercially available granular-form base materials with commercially available copolymer additives. The material composition was 80 wt-% P(L/DL)LA (70/30) and 20 wt-% PLLA/TMC (70/30). The components were weighed according to a desired weight ratio into a container which was then rotated in a Turbula T2F shaker mixer for 30 minutes until a homogenous dry mixture was obtained. The resulting mixture was then dried in vacuum at 60° C. for 8 to 12 hours and thereafter melt-blended and injection-moulded in to plate-shaped test pieces. The injection-moulding machine used was a fully electric Fanuc Roboshot Alpha i30A injection-moulding machine with a mould clamping force of 300 kN. The injection unit was equipped with high speed (max. 66 cm3/s to 330 mm/s), high pressure (max. 2500 bar) injection options. The barrel diameter was 16 mm and it was equipped with three-band heater zones, a standard profile anticorrosion screw and a standard open nozzle with a 2.5 mm hole. The extruder melt-blending and homogenization conditions of the material during the metering phase of the process included a back pressure of 40 to 60 bar, a screw speed of 60 to 100 rpm and barrel temperatures of 160 to 230° C. Injection moulding conditions included a nozzle temperature of 180 to 230° C., an injection speed of 80 to 300 mm/s, a maximum injection pressure of 2500 bar, a pack pressure of 1000 to 2300 bar for 3 to 8 s, a cooling time of 10 to 22 s and a mould temperature of 20 to 30° C. The total cycle time was 20 to 40 s consisting of the following phases during one injection-moulding process cycle: closing of the mould, injection of the molten polymer into the mould, pack pressure, cooling while extruder was metering for the next cycle during cooling phase, opening the mould and ejection of article from the mould.
  • The plates were sterilized by gamma irradiation with a nominal dose of 25 kGy. After sterilisation, the plates were submerged in NMP (1-Methyl-2-pyrrolidinone, 99%, Acros Organics, Inc., USA) for 30 seconds. After submerging the plates were set for 30 minutes on a plastic holder at room conditions at 20° C. Thickness, length and mass of the plates were measured before submerging and 30 minutes thereafter. Dimensions were measured with a slide gauge and mass with an analysis balance. Additionally, 30, 60 and 120 minutes after the submerging of the plate, it was bent to 45° angle to find out softening and bending characteristics of the plate. The diffusion depth of the NMP was analysed with SmartScope Flash optical 3D-measuring device. Approximately 1 mm of the material was cut off from the edge of the plate. The depth of the diffusion was measured from the cut cross-section of the plate 120 minutes after submerging. The results of the NMP diffusion after 30 min of submerging are shown in table 3.
    TABLE 3
    Mass and dimensions of the plate before and after
    submerging in the NMP
    Mass Thickness
    Mass of the of the
    of the NMP outer
    plate in the Thickness layer Length
    (mg) plate (mg) (mm) (mm) (mm)
    Initial 470.8 — 1.01 0 23.5
    30 min after 575.7 104.9 1.15 0.15 23.6
    submerging
  • The thickness of the plate was increased 13% and its mass was increased 22% due to the submerging of the plate in NMP. The increase of the mass can be seen as the diffusion of NMP into the plate. The increase of the thickness is due to the swelling of the outer layer of the plate. The thickness of the swollen outer layer of the plate was ca. 0.15 mm. The length was not changed due to the submerging. Moreover, 30 minutes after submerging the plate was softened and bendable by hand.
  • Resorbable polymer matrix absorbs NMP when immersed into it. Thereafter, an implant loaded with NMP is implanted into the body, and NMP is released gradually during a certain period of time. If the rate of releasing is appropriate, NMP owns osteogenic properties. As with almost any pharmaceuticals, the concentration of NMP must be within certain limits, called a therapeutic window. Below the window, NMP is inefficacious. Correspondingly, above the window, NMP presents an adverse event by inhibiting certain proteins, other molecules or cell lines. The NMP content is preferably between 0.05 and 50 weight- %, more preferably between 0.1 and 10 weight-%.
  • According to one preferred embodiment of the method of the present invention, NMP is mixed with a polymer matrix or one of its components before the polymer matrix is fashioned into the form of a medical implant. The mixing can take place in an extruder, in a mixer or similar equipment known per se.
  • NMP may be applied to the implant as well by packing said implant into a container with NMP already in the production process. NMP will be absorbed to the polymer matrix of the implant during storage in said container.
  • The polymer composition of the present invention can be fashioned into implants by injection moulding, compression moulding, extrusion or with another melt-moulding process known by persons skilled in the art.
    • EXAMPLE 4
  • Example 4 presents one preferred embodiment of the present invention, where the implant is a barrier membrane in Guided Tissue Regeneration (GTR) to treat a periodontal defect.
  • The membrane comprises PLA/PGA-matrix polymers. The membrane is packaged in a slot of a package, such as a plastic blister. The preparation of the membrane is conducted as one stage of surgical operation as follows:
  • 1. After opening the package, a proper amount of NMP is poured into the membrane slot. The membrane is fully immersed in NMP for an adequate period, for example 30 seconds to 3 minutes, preferably for 30 seconds.
  • 2. The membrane is removed from the slot.
  • 3. NMP is allowed to diffuse into the polymer matrix of the membrane for 15 to 20 minutes.
  • 4. The membrane is ready for use as a barrier between the gingival soft tissue and the healing bone tissue and/or periodontal tissues in order to prevent the gingival soft tissue filling the defect side. In the conditions of a normal operating theater temperature and humidity, the membrane stays malleable for several hours.
  • Implants of the invention can be used for example in guided bone regeneration applications, where the effect of a NMP loaded barrier membrane is required to avoid soft tissue ingrowth in the area where new bone formation is required, and to enhance bone regeneration.
  • It will be obvious to a person skilled in the art that, as the technology advances, the inventive concept can be implemented in various ways. The invention and its embodiments are not limited to the examples described above but may vary within the scope of the claims.

Claims (8)

1. A method of promoting osteogenesis comprising the steps of:
providing a resorbable polymer composition comprising a base material including a polymer matrix of resorbable polymer(s) or copolymer(s), and N-methyl-2-pyrrolidone (NMP), wherein NMP is present in an amount imparting osteogenic properties for the composition, and
implanting the resorbable polymer composition into a recipient to promote osteogenesis.
2-11. (canceled)
12. The method of claim 1, wherein NMP is present in an amount between 0.05 and 50 weight- %.
13. A method of promoting osteogenesis comprising the steps of:
selecting polymer(s) or copolymer(s),
adding NMP to the polymer(s) or copolymer(s) in an amount imparting osteogenic properties to the polymer(s) or copolymer(s),
mixing the polymer(s) or copolymer(s) to form a polymer matrix,
forming an implant from the polymer matrix, and
implanting the implant into a recipient to promote osteogenesis.
14. The method of claim 1, wherein the polymer matrix is selected from a group consisting of polyglycolide, polylactides, polycaprolactones, polytrimethylenecarbonates, polyhydroxybutyrates, polyhydroxyvalerates, polydioxanones, polyorthoesters, polycarbonates, polytyrosinecarbonates, polyorthocarbonates, polyalkylene oxalates, polyalkylene succinates, poly(malic acid), poly(maleic anhydride), polypeptides, polydepsipeptides, polyvinylalcohol, polyesteramides, polyamides, polyanhydrides, polyurethanes, polyphosphazenes, polycyanoacrylates, polyfumarates, poly(amino acids), modified polysaccharides, modified proteins and their copolymers, terpolymers or combinations or mixtures or polymer blends thereof.
15. The method of claim 1, wherein the polymer matrix is selected from the group consisting of polyglycolide, poly(L-lactide-co-glycolide), poly(D,L-lactide-co-glycolide), poly(L-lactide), poly(D,L-lactide), poly(L-lactide-co-D,L-lactide), polycaprolactone, poly(L-lactide-co-caprolactone), poly(D,L-lactide-co-caprolactone) polytrimethylenecarbonate, poly(L-lactide-co-trimethylenecarbonate), poly(D,L-lactide-co-trimethylenecarbonate), polydioxanone and their copolymers, terpolymers or combinations or mixtures or polymer blends thereof.
16. A method of promoting osteogenesis comprising the steps of:
selecting polymer(s) or copolymer(s) to form a polymer matrix,
forming an implant from said polymer matrix,
adding NMP to the implant, and
implanting the implant into a recipient to promote osteogenesis.
17. The method of claim 16, wherein NMP is added to the implant preoperatively.
US11/104,771 2001-12-04 2005-04-13 Method of promoting osteogenesis Abandoned US20050186251A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/104,771 US20050186251A1 (en) 2001-12-04 2005-04-13 Method of promoting osteogenesis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/006,800 US6926903B2 (en) 2001-12-04 2001-12-04 Resorbable polymer composition, implant and method of making implant
US11/104,771 US20050186251A1 (en) 2001-12-04 2005-04-13 Method of promoting osteogenesis

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/006,800 Division US6926903B2 (en) 2001-12-04 2001-12-04 Resorbable polymer composition, implant and method of making implant

Publications (1)

Publication Number Publication Date
US20050186251A1 true US20050186251A1 (en) 2005-08-25

Family

ID=21722648

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/006,800 Expired - Fee Related US6926903B2 (en) 2001-12-04 2001-12-04 Resorbable polymer composition, implant and method of making implant
US11/104,771 Abandoned US20050186251A1 (en) 2001-12-04 2005-04-13 Method of promoting osteogenesis

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US10/006,800 Expired - Fee Related US6926903B2 (en) 2001-12-04 2001-12-04 Resorbable polymer composition, implant and method of making implant

Country Status (9)

Country Link
US (2) US6926903B2 (en)
EP (1) EP1458429A1 (en)
JP (1) JP4323954B2 (en)
KR (1) KR100863803B1 (en)
CN (1) CN100462106C (en)
AU (1) AU2002346767B2 (en)
BR (1) BR0214663A (en)
CA (1) CA2468471A1 (en)
WO (1) WO2003047646A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8541028B2 (en) 2004-08-04 2013-09-24 Evonik Corporation Methods for manufacturing delivery devices and devices thereof
US8728528B2 (en) 2007-12-20 2014-05-20 Evonik Corporation Process for preparing microparticles having a low residual solvent volume
US9107979B2 (en) 2012-12-06 2015-08-18 Industrial Technology Research Institute Bioresorbable porous film

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1344538A1 (en) * 2002-03-14 2003-09-17 Degradable Solutions AG Porous biodegradable implant material and method for its fabrication
JP2006175153A (en) * 2004-12-24 2006-07-06 Goodman Co Ltd Biodegradable bio-absorbable material for clinical practice
US7074412B2 (en) * 2003-01-30 2006-07-11 The University Of Zurich Pharmaceutical composition
JP2006526424A (en) * 2003-06-04 2006-11-24 イニオン リミテッド Biodegradable implant and method for producing the same
JP2005062846A (en) 2003-07-31 2005-03-10 Canon Inc Electrophotographic photoreceptor
US7189409B2 (en) * 2004-03-09 2007-03-13 Inion Ltd. Bone grafting material, method and implant
US8163030B2 (en) * 2004-05-06 2012-04-24 Degradable Solutions Ag Biocompatible bone implant compositions and methods for repairing a bone defect
US20060257448A1 (en) * 2005-05-10 2006-11-16 The University Of Zurich Resorbable polymer composition, implant and method of making implant
US20060258578A1 (en) * 2005-05-10 2006-11-16 The University Of Zurich Pharmaceutical composition
US20080003196A1 (en) * 2006-06-30 2008-01-03 Jonn Jerry Y Absorbable cyanoacrylate compositions
JP2010508071A (en) * 2006-10-31 2010-03-18 シンセス ゲーエムベーハー Polymer-ceramic composites and methods
GB2446652A (en) * 2007-02-16 2008-08-20 Inion Ltd Osteogenic compounds
GB2446653A (en) * 2007-02-16 2008-08-20 Inion Ltd Osteogenic compounds
WO2008132458A1 (en) * 2007-04-30 2008-11-06 Inion Limited Compositions useful in the modulation of immune responses and the treatment or prevention of inflammatory responses and related methods
GB2451451A (en) * 2007-07-30 2009-02-04 Inion Ltd Osteogenic compounds
US8323322B2 (en) * 2007-10-05 2012-12-04 Zimmer Spine, Inc. Medical implant formed from porous metal and method
US8124601B2 (en) * 2007-11-21 2012-02-28 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US8129477B1 (en) 2008-08-06 2012-03-06 Medtronic, Inc. Medical devices and methods including blends of biodegradable polymers
EP2269663B1 (en) 2009-07-03 2018-03-07 Armbruster Biotechnology GmbH Bone graft and biocomposite
US8551525B2 (en) 2010-12-23 2013-10-08 Biostructures, Llc Bone graft materials and methods
US10207027B2 (en) 2012-06-11 2019-02-19 Globus Medical, Inc. Bioactive bone graft substitutes
EP3231453B1 (en) 2016-04-14 2019-12-25 Immundiagnostik AG Bone sialoprotein(bsp)-functionalised bone replacement bodies
US12383246B2 (en) 2020-10-12 2025-08-12 Abbott Cardiovascular Systems, Inc. Vessel closure device with improved safety and tract hemostasis

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5077049A (en) * 1989-07-24 1991-12-31 Vipont Pharmaceutical, Inc. Biodegradable system for regenerating the periodontium
US5378472A (en) * 1990-11-26 1995-01-03 Merck Patent Gesellschaft Mit Beschrankter Haftung Methyl pyrrolidinone chitosan, production process and uses thereof
US5725491A (en) * 1988-10-03 1998-03-10 Atrix Laboratories, Inc. Method of forming a biodegradable film dressing on tissue
US5939323A (en) * 1996-05-28 1999-08-17 Brown University Hyaluronan based biodegradable scaffolds for tissue repair
US6162537A (en) * 1996-11-12 2000-12-19 Solutia Inc. Implantable fibers and medical articles
US6245345B1 (en) * 1998-07-07 2001-06-12 Atrix Laboratories, Inc. Filamentous porous films and methods for producing the same
US6261583B1 (en) * 1998-07-28 2001-07-17 Atrix Laboratories, Inc. Moldable solid delivery system

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ308658A (en) 1995-06-05 1999-10-28 Takeda Chemical Industries Ltd Sustained release synergistic pharmaceutical composition comprising a non-peptide osteogenetic promoting substance and a biodegradable polymer
US5910492A (en) * 1995-06-05 1999-06-08 Takeda Chemical Industries, Ltd. Osteogenic promoting pharmaceutical composition
CA2413157A1 (en) 2000-06-28 2002-01-03 Atul J. Shukla Biodegradable vehicles and delivery systems of biologically active substances
CN1206001C (en) * 2000-06-28 2005-06-15 A·J·舒克拉 Biodegradable Carriers and Biodegradable Delivery Systems

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5725491A (en) * 1988-10-03 1998-03-10 Atrix Laboratories, Inc. Method of forming a biodegradable film dressing on tissue
US5077049A (en) * 1989-07-24 1991-12-31 Vipont Pharmaceutical, Inc. Biodegradable system for regenerating the periodontium
US5378472A (en) * 1990-11-26 1995-01-03 Merck Patent Gesellschaft Mit Beschrankter Haftung Methyl pyrrolidinone chitosan, production process and uses thereof
US5939323A (en) * 1996-05-28 1999-08-17 Brown University Hyaluronan based biodegradable scaffolds for tissue repair
US6162537A (en) * 1996-11-12 2000-12-19 Solutia Inc. Implantable fibers and medical articles
US6245345B1 (en) * 1998-07-07 2001-06-12 Atrix Laboratories, Inc. Filamentous porous films and methods for producing the same
US6261583B1 (en) * 1998-07-28 2001-07-17 Atrix Laboratories, Inc. Moldable solid delivery system

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8541028B2 (en) 2004-08-04 2013-09-24 Evonik Corporation Methods for manufacturing delivery devices and devices thereof
US8728528B2 (en) 2007-12-20 2014-05-20 Evonik Corporation Process for preparing microparticles having a low residual solvent volume
US9107979B2 (en) 2012-12-06 2015-08-18 Industrial Technology Research Institute Bioresorbable porous film

Also Published As

Publication number Publication date
JP2005511800A (en) 2005-04-28
KR100863803B1 (en) 2008-10-16
US6926903B2 (en) 2005-08-09
EP1458429A1 (en) 2004-09-22
JP4323954B2 (en) 2009-09-02
US20030104029A1 (en) 2003-06-05
BR0214663A (en) 2004-11-03
KR20040081740A (en) 2004-09-22
CN1599629A (en) 2005-03-23
AU2002346767B2 (en) 2007-08-09
AU2002346767A1 (en) 2003-06-17
CA2468471A1 (en) 2003-06-12
WO2003047646A1 (en) 2003-06-12
WO2003047646A8 (en) 2004-05-27
CN100462106C (en) 2009-02-18

Similar Documents

Publication Publication Date Title
US6926903B2 (en) Resorbable polymer composition, implant and method of making implant
Mainil-Varlet et al. Long-term in vivo degradation and bone reaction to various polylactides: 1. One-year results
EP1229858B1 (en) Biodegradable polymer/ceramic implant material with bimodal degradation profile
RU2583007C2 (en) Bioabsorbable polymer compositions, methods of processing same and medical devices made therefrom
ES2535484T3 (en) Polymer-bone composite material that can be formed or configured and method for its production
US8197838B2 (en) Sustained release systems of ascorbic acid phosphate
Ignatius et al. A composite polymer/tricalcium phosphate membrane for guided bone regeneration in maxillofacial surgery
EP0994736B1 (en) Novel plastic based composite and its use
US7419681B2 (en) Method to enhance drug release from a drug-releasing material
US20060257448A1 (en) Resorbable polymer composition, implant and method of making implant
Nieminen et al. In vivo and in vitro degradation of a novel bioactive guided tissue regeneration membrane
Olaechea et al. Biodegradation of three different collagen membranes: A histological study
BR112019005021B1 (en) BONE IMPLANT AND ITS MANUFACTURING METHOD
WO2000018443A1 (en) Melt-mouldable composites
CA2555320A1 (en) Bioabsorbable implantable substrate
Deng et al. Effects of Thermal History and Physical Aging on Thermal Properties of Poly-L
Hutmacher et al. The clinical evaluation of a bioresorbable minipin

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO PAY ISSUE FEE